{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:14:31Z","timestamp":1791231271431,"version":"4.1.0"},"reference-count":231,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.clindermatol.2018.04.004","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T14:27:04Z","timestamp":1523543224000},"page":"459-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Systemic sclerosis: Current concepts of skin and systemic manifestations"],"prefix":"10.1016","volume":"36","author":[{"given":"David R.","family":"Pearson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pappas-Taffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2018.04.004_bb0005","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0889-857X(03)00022-X","article-title":"Scleroderma epidemiology","volume":"29","author":"Mayes","year":"2003","journal-title":"Rheum Dis Clin"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MD.0b013e31829be125","article-title":"Race and association with disease manifestations and mortality in scleroderma","volume":"92","author":"Gelber","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/annrheumdis-2014-206386","article-title":"A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study","volume":"75","author":"Elhai","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/art.1780400421","article-title":"Racial differences in scleroderma among women in Michigan","volume":"40","author":"Laing","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0030","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s10067-011-1751-0","article-title":"Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies","volume":"30","author":"Krzyszczak","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/rheumatology\/keq294","article-title":"Gender and ethnicity differences in patients with diffuse systemic sclerosis\u2014analysis from three large randomized clinical trials","volume":"50","author":"Nashid","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0040","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/art.34482","article-title":"A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis","volume":"64","author":"Steen","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0045","first-page":"1004","article-title":"Childhood onset systemic sclerosis: Classification, clinical and serologic features, and survival in comparison with adult onset disease","volume":"33","author":"Scalapino","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0050","first-page":"1","article-title":"Cutaneous manifestations of scleroderma and scleroderma-like disorders: A comprehensive review","author":"Ferreli","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0055","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: An american college of rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"Van Den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0060","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/BOR.0000000000000325","article-title":"Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis","volume":"28","author":"Choi","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0075","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/annrheumdis-2015-207271","article-title":"Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: A 10-year longitudinal study from the EUSTAR database","volume":"75","author":"Wirz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0080","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1,012 Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0085","first-page":"74","article-title":"One decade distinct features, morbidity and mortality of scleroderma: A cross-sectional study","volume":"34","author":"Nazarinia","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/art.1780280114","article-title":"Evolution of primary raynaud\u2019s phenomenon (raynaud\u2019s disease) to connective tissue disease","volume":"28","author":"Gerbracht","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0095","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosi","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0100","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","article-title":"Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: Evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis","volume":"73","author":"Minier","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0105","first-page":"2423","article-title":"Natural history of ischemic digital ulcers in systemic sclerosis: Single-center retrospective longitudinal study","volume":"34","author":"Hachulla","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0110","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"suppl 3","key":"10.1016\/j.clindermatol.2018.04.004_bb0115","first-page":"iii19","article-title":"Digital ulcers: Overt vascular disease in systemic sclerosis","volume":"48","author":"Steen","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0120","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/annrheumdis-2011-200631","article-title":"Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry","volume":"71","author":"Denton","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"suppl 76","key":"10.1016\/j.clindermatol.2018.04.004_bb0125","article-title":"Functional impairment of systemic scleroderma patients with digital ulcerations: Results from the DUO registry","volume":"31","author":"Guillevin","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0130","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/03009742.2013.780095","article-title":"A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact","volume":"42","author":"Ennis","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0140","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/acr.20336","article-title":"Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the canadian scleroderma research group registry","volume":"63","author":"Khimdas","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0145","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/art.24394","article-title":"Capillaroscopic skin ulcer risk index: A new prognostic tool for digital skin ulcer development in systemic sclerosis patients","volume":"61","author":"Sebastiani","year":"2009","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/annrheumdis-2011-200022","article-title":"Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study","volume":"71","author":"Sebastiani","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/CH-141809","article-title":"Prediction risk chart for scleroderma digital ulcers: A composite predictive model based on capillaroscopic, demographic and clinico-serological parameters","volume":"59","author":"Manfredi","year":"2015","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0160","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/ard.2010.132431","article-title":"Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions","volume":"70","author":"Smith","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0165","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U","article-title":"Improvement in skin thickening in systemic sclerosis associated with improved survival","volume":"44","author":"Steen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0170","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0889-857X(03)00023-1","article-title":"Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being","volume":"29","author":"Medsger","year":"2003","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0175","first-page":"269","article-title":"Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma","volume":"33","author":"Chang","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10067-006-0302-6","article-title":"The natural course of progressive systemic sclerosis patients with interstitial lung involvement","volume":"26","author":"Benan","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0185","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/1756-185X.13203","article-title":"A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults","volume":"20","author":"Morrisroe","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0190","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","article-title":"Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial","volume":"43","author":"Clements","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0195","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (Modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/03009740410006060","article-title":"Daily activities and hand function in women with scleroderma","volume":"33","author":"Sandqvist","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0205","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1756-185X.2012.01810.x","article-title":"The frequency of sicca symptoms and Sjogren\u2019s syndrome in patients with systemic sclerosis","volume":"16","author":"Kobak","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0210","first-page":"322","article-title":"Orofacial manifestations of scleroderma. A literature review","volume":"117","author":"Hadj Said","year":"2016","journal-title":"Rev Stomatol Chir Maxillofac Chir Orale"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0215","first-page":"637","article-title":"Increased incidence of carcinoma of the tongue in patients with systemic sclerosis","volume":"32","author":"Derk","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0220","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0190-9622(98)70001-5","article-title":"Cutaneous deposition diseases. Part II","volume":"39","author":"Touart","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0225","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.semarthrit.2016.05.008","article-title":"Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study","volume":"46","author":"Valenzuela","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0230","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/BOR.0000000000000220","article-title":"Calcinosis: pathophysiology and management","volume":"27","author":"Valenzuela","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0235","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.semarthrit.2010.06.008","article-title":"Hand radiological damage in systemic sclerosis: Comparison with a control group and clinical and functional correlations","volume":"40","author":"Koutaissoff","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0240","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.2010.134304","article-title":"Predictive factors of hand radiographic lesions in systemic sclerosis: a prospective study","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0245","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/1523-1747.ep12522736","article-title":"Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases","volume":"81","author":"Braverman","year":"1983","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0250","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2230.2008.03148.x","article-title":"Clinical and laboratory features of Japanese patients with scleroderma and telangiectasia","volume":"34","author":"Ashida","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0255","first-page":"106","article-title":"Telangiectasia as a potential clinical marker of microvascular lesions in systemic sclerosis patients from EUSTAR data in China","volume":"33","author":"Zhang","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0260","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/acr.22766","article-title":"Skin telangiectasia identify a subset of systemic sclerosis patients with severe vascular disease","volume":"68","author":"Hurabielle","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0265","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3899\/jrheum.090697","article-title":"Telangiectases in scleroderma: A potential clinical marker of pulmonary arterial hypertension","volume":"37","author":"Shah","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0270","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3899\/jrheum.130171","article-title":"Association of dermoscopic profiles of telangiectases with nailfold videocapillaroscopic patterns in patients with systemic sclerosis","volume":"40","author":"Giampetruzzi","year":"2013","journal-title":"J Rheumatol"},{"issue":"suppl 76","key":"10.1016\/j.clindermatol.2018.04.004_bb0275","first-page":"S12","article-title":"A pilot study of body image dissatisfaction and the psychological impact of systemic sclerosis-related telangiectases","volume":"31","author":"Ennis","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0280","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/acr.20257","article-title":"Association of pruritus with quality of life and disability in systemic sclerosis","volume":"62","author":"El-Baalbaki","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpainsymman.2015.12.314","article-title":"The impact of pain and itch on functioning and health-related quality of life in systemic sclerosis: An exploratory study","volume":"52","author":"Racine","year":"2016","journal-title":"J Pain Symptom Manag"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0290","first-page":"2056","article-title":"Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: An updated analysis of 959 patients","volume":"52","author":"Razykov","year":"2013","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0295","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/bjd.14998","article-title":"Itch and systemic sclerosis: frequency, clinical characteristics and consequences","volume":"176","author":"Th\u00e9r\u00e9n\u00e9","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0300","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archderm.1983.01650260037013","article-title":"Vitiligolike macules in systemic scleroderma","volume":"119","author":"Sanchez","year":"1983","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0305","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2340\/0001555564485492","article-title":"Clinical appearance of skin lesions and disturbances of pigmentation in localized scleroderma","volume":"64","author":"Serup","year":"1984","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0310","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0190-9622(84)70163-0","article-title":"A new skin manifestation of progressive systemic sclerosis","volume":"11","author":"Jawitz","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0315","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2230.2004.01683.x","article-title":"Reticulate hyperpigmented scleroderma: a new pigmentary manifestation","volume":"30","author":"Ee","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0320","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13256-015-0697-2","article-title":"Reticulate hyperpigmentation in systemic sclerosis: a case report and review of the literature","volume":"9","author":"Chuamanochan","year":"2015","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0325","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/ced.12752","article-title":"Pigmented skin patches without scleroderma as a predominant clinical symptom revealing systemic sclerosis","volume":"41","author":"Darrigade","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0330","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/1756-185X.13049","article-title":"Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis","volume":"20","author":"Solanki","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0335","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1600-0749.2006.00326.x","article-title":"In vivo and in vitro evidence of dermal fibroblasts influence on human epidermal pigmentation","volume":"19","author":"Cario-Andr\u00e9","year":"2006","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0340","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jaad.2016.11.024","article-title":"Nail involvement in systemic sclerosis","volume":"76","author":"Marie","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0345","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: Systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0350","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0355","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0360","first-page":"245","article-title":"Cost-of-illness in systemic sclerosis: a retrospective study of an Italian cohort of 106 patients","volume":"55","author":"Belotti Masserini","year":"2003","journal-title":"Reumatismo"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0365","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/acr.22167","article-title":"Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain","volume":"66","author":"L\u00f5pez-Bastida","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0370","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3109\/03009742.2014.976653","article-title":"The economic burden and health-related quality of life associated with systemic sclerosis in France","volume":"44","author":"Chevreul","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0375","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3899\/jrheum.120600","article-title":"Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population","volume":"39","author":"Furst","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0380","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0385","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","article-title":"BSR and BHPR guideline for the treatment of systemic sclerosis","volume":"55","author":"Denton","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0390","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/art.10685","article-title":"Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis","volume":"46","author":"Harrison","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0395","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaad.2008.11.025","article-title":"Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing","volume":"60","author":"Alivernini","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0400","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","article-title":"Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis","volume":"44","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"Suppl C","key":"10.1016\/j.clindermatol.2018.04.004_bb0405","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/eurheartj\/4.suppl_C.123","article-title":"Calcium entry blocking agents in digital vasospasm (Raynaud\u2019s phenomenon)","volume":"4","author":"Kahan","year":"1983","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0410","first-page":"880","article-title":"Controlled double-blind trial of nifedipine in the treatment of Raynaud\u2019s phenomenon","volume":"308","author":"Rodeheffer","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0415","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/oxfordjournals.eurheartj.a061923","article-title":"Nifedipine and alpha 1-adrenergic blockade in Raynaud\u2019s phenomenon","volume":"6","author":"Kahan","year":"1985","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0420","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/000331978703800407","article-title":"Nicardipine in the treatment of Raynaud\u2019s phenomenon: A randomized double-blind trial","volume":"38","author":"Kahan","year":"1987","journal-title":"Angiology"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0425","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2133.1987.tb04122.x","article-title":"Nifedipine in the treatment of Raynaud\u2019s phenomenon in patients with systemic sclerosis","volume":"117","author":"Thomas","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0430","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","article-title":"Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud\u2019s phenomenon in patients with systemic sclerosis: a double blind randomised study","volume":"298","author":"Rademaker","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0435","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0440","first-page":"284","article-title":"Nifedipine in Raynaud\u2019s phenomenon: relationship between immediate, short term and longterm effects","volume":"14","author":"Kallenberg","year":"1987","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0445","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud\u2019s phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0450","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0455","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3899\/jrheum.090270","article-title":"Randomized placebo-controlled crossover trial of tadalafil in Raynaud\u2019s phenomenon secondary to systemic sclerosis","volume":"36","author":"Schiopu","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0460","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud\u2019s phenomenon resistant to vasodilator therapy: A double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0465","first-page":"2086","article-title":"Efficacy of tadalafil in Raynaud\u2019s phenomenon secondary to systemic sclerosis: a double-blind randomized placebo-controlled parallel group multicentric study [Abstract]","volume":"62","author":"Agarwal","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0470","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","article-title":"Modified-release sildenafil reduces Raynaud\u2019s phenomenon attack frequency in limited cutaneous systemic sclerosis","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0475","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinternmed.2012.2271","article-title":"Vardenafil for the treatment of Raynaud phenomenon: A randomized, double-blind, placebo-controlled crossover study","volume":"172","author":"Caglayan","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0480","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","article-title":"Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis","volume":"65","author":"Tingey","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0485","article-title":"Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0490","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.47.1.43","article-title":"Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud\u2019s phenomenon in systemic sclerosis","volume":"47","author":"McHugh","year":"1988","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0495","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/rheumatology\/27.3.220","article-title":"Successful treatment of Raynaud\u2019s syndrome with iloprost, a chemically stable prostacyclin analogue","volume":"27","author":"Yardumian","year":"1988","journal-title":"Rheumatology"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0500","first-page":"1403","article-title":"Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud\u2019s phenomenon","volume":"19","author":"Kyle","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0505","first-page":"1407","article-title":"Intravenous iloprost treatment of Raynaud\u2019s phenomenon and ischemic ulcers secondary to systemic slcerosis","volume":"19","author":"Wigley","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0510","first-page":"35","article-title":"A randomised, double-blind study of Cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud\u2019s phenomenon secondary to systemic sclerosis","volume":"11","author":"Lau","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0515","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double- blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0520","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.54.3.197","article-title":"Oral iloprost as a treatment for Raynaud\u2019s syndrome: a double blind multicentre placebo controlled study","volume":"54","author":"Belch","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0525","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","article-title":"Oral iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study","volume":"41","author":"Wigley","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0530","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/rheumatology\/37.9.952","article-title":"Oral iloprost in Raynaud\u2019s phenomenon secondary to systemic sclerosis: A multicentre, placebo-controlled, dose-comparison study","volume":"37","author":"Black","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0535","first-page":"2173","article-title":"Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis","volume":"26","author":"Vayssairat","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0540","first-page":"2483","article-title":"Digital ischemic ulcers in scleroderma treated with oral treprostinil diethanolamine: A randomized, double-blind, placebo-controlled, multicenter study","volume":"63","author":"Seibold","year":"2011","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0545","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud\u2019s phenomenon. A randomized, controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0550","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/03009740310004711","article-title":"Comparison between iloprost and alprostadil in the treatment of Raynaud\u2019s phenomenon","volume":"33","author":"Marasini","year":"2004","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0555","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00005344-199509000-00007","article-title":"Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud\u2019s phenomenon: The acute vasodilatory effect is not sustained","volume":"26","author":"Kingma","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0560","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/rheumatology\/keq077","article-title":"Effect of bosentan on skin fibrosis in patients with systemic sclerosis: A prospective, open-label, non-comparative trial","volume":"49","author":"Kuhn","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0565","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0570","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3899\/jrheum.100358","article-title":"Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension","volume":"37","author":"Rosato","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0575","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/rheumatology\/kep413","article-title":"Effect of the dual endothelin receptor antagonist bosentan on Raynaud\u2019s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study","volume":"49","author":"Nguyen","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0580","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","article-title":"Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials","volume":"315","author":"Khanna","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0585","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.3899\/jrheum.160592","article-title":"Effects of longterm treatment with bosentan and iloprost on nailfold absolute capillary number, fingertip blood perfusion, and clinical status in systemic sclerosis","volume":"43","author":"Trombetta","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0590","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2047-783X-19-2","article-title":"Retrospective analysis of the frequency of centrofacial telangiectasia in systemic sclerosis patients treated with bosentan or ilomedin","volume":"19","author":"Hetzer","year":"2014","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0595","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0600","first-page":"1801","article-title":"Statins: Potentially useful in therapy of systemic sclerosis-related Raynaud\u2019s phenomenon and digital ulcers","volume":"35","author":"Abou-Raya","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0605","article-title":"Prazosin for Raynaud\u2019s phenomenon in progressive systemic sclerosis","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0610","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/archderm.1984.01650390051010","article-title":"A double-blind study of prazosin in the treatment of Raynaud\u2019s phenomenon in scleroderma","volume":"120","author":"Surwit","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0615","first-page":"94","article-title":"Prazosin treatment of Raynaud\u2019s phenomenon: A double blind single crossover study","volume":"12","author":"Russell","year":"1985","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0620","first-page":"948","article-title":"A double-blind, randomized, placebo-controlled crossover trial of the \u03b12c-adrenoceptor antagonist orm-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis","volume":"53","author":"Herrick","year":"2014","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0625","first-page":"2257","article-title":"Intravenous N-acetylcysteine for treatment of Raynaud\u2019s phenomenon secondary to systemic sclerosis: A pilot study","volume":"28","author":"Sambo","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0630","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/039463200501800420","article-title":"Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynauds phenomenon","volume":"18","author":"Salsano","year":"2005","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0635","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s10067-009-1251-7","article-title":"The treatment with N-acetylcysteine of Raynaud\u2019s phenomenon and ischemic ulcers therapy in sclerodermic patients: A prospective observational study of 50 patients","volume":"28","author":"Rosato","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0640","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.rbr.2014.07.001","article-title":"Oral N-acetylcysteine in the treatment of Raynaud\u2019s phenomenon secondary to systemic sclerosis: A randomized, double-blind, placebo-controlled clinical trial","volume":"54","author":"Correa","year":"2014","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0645","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","article-title":"Prevention of vascular damage in scleroderma and autoimmune Raynaud\u2019s phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril","volume":"56","author":"Gliddon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0650","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud\u2019s phenomenon","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0655","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1136\/annrheumdis-2012-201536","article-title":"A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon","volume":"72","author":"Hummers","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0660","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","article-title":"Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary raynaud\u2019s phenomenon","volume":"34","author":"Teh","year":"1995","journal-title":"Rheumatology"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0665","first-page":"51","article-title":"Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis","volume":"27","author":"Fiori","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0670","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.1780280311","article-title":"Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis","volume":"28","author":"Williams","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0675","first-page":"168","article-title":"Cervicothoracic sympathectomy for Raynaud\u2019s syndrome","volume":"12","author":"Lowell","year":"1993","journal-title":"Int Angiol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0680","first-page":"1788","article-title":"A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia","volume":"30","author":"Kotsis","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0685","first-page":"676","article-title":"Thoracic sympathectomy for upper extremity Ischemia","volume":"64","author":"Hoexum","year":"2016","journal-title":"Minerva Cardioangiol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0690","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1177\/1753193413516242","article-title":"A prospective study of the use of botulinum toxin injections in the treatment of Raynaud\u2019s syndrome associated with scleroderma","volume":"39","author":"Uppal","year":"2014","journal-title":"J Hand Surg Eur Vol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0695","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1346-8138.13030","article-title":"Beneficial effect of botulinum toxin A on Raynaud\u2019s phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study","volume":"43","author":"Motegi","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0700","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud\u2019s phenomenon: A randomized, double-blind, placebo-controlled clinical trial assessing","volume":"69","author":"Bello","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0705","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0710","first-page":"71","article-title":"Placebo controlled trial of methotrexate in systemic sclerosis","volume":"14","author":"Das","year":"2005","journal-title":"Mymensingh Med J"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0715","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0720","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3899\/jrheum.071169","article-title":"Shifting our thinking about uncommon disease trials: The case of methotrexate in scleroderma","volume":"36","author":"Johnson","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0725","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: Post-hoc analyses from the Scleroderma Lung Study I and II","author":"Namas","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0730","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood.V100.5.1602.h81702001602_1602_1610","article-title":"High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes","volume":"100","author":"McSweeney","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0735","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/03009740510026896","article-title":"Low-dose intravenous cyclophosphamide in systemic sclerosis: An open prospective efficacy study in patients with early diffuse disease","volume":"35","author":"Valentini","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0740","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0745","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124205","article-title":"Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review","volume":"10","author":"Omair","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0750","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/1756-185X.13035","article-title":"Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease","volume":"20","author":"Boulos","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0755","first-page":"151","article-title":"A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0760","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3899\/jrheum.140833","article-title":"Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis","volume":"42","author":"Poelman","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0765","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","article-title":"Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature","volume":"16","author":"Sanges","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0770","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0775","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0780","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0785","first-page":"148","article-title":"Assessment of sensitivity to change of the European Scleroderma Study Group activity index","volume":"34","author":"Melsens","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0790","series-title":"Rituximab in Systemic Sclerosis (RECOVER)","author":"Clinicaltrials.gov [Internet]","year":"2012"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0795","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/ard.2008.096123","article-title":"An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis","volume":"68","author":"Denton","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0800","first-page":"S40","article-title":"Is there a role for TNF\u03b1 antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique","volume":"29","author":"Distler","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0805","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10067-013-2422-0","article-title":"Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries","volume":"33","author":"Iudici","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"9790","key":"10.1016\/j.clindermatol.2018.04.004_bb0810","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.clindermatol.2018.04.004_bb9005","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb9010","series-title":"Scleroderma: Cyclophosphamide or transplantation (SCOT).","author":"Clinicaltrials.gov [Internet]","year":"2005"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0815","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ard.2007.071464","article-title":"Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis","volume":"67","author":"Vonk","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0820","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2009.013458","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases","volume":"95","author":"Farge","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0825","article-title":"A phase 2 study of safety and efficacy of anabasum (JBT-101), a cannabinoid receptor type 2 agonist, in diffuse cutaneous systemic sclerosis [abstract]","volume":"69","author":"Spiera","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0830","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0835","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: A EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0840","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","article-title":"Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis","volume":"17","author":"Chakravarty","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0845","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","article-title":"Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0850","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1365-2133.2012.11186.x","article-title":"Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: A phase II multicentre randomized double-blinded controlled trial","volume":"167","author":"Prey","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0855","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0860","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/art.24986","article-title":"Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study","volume":"60","author":"Su","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0865","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1600-0781.2007.00308.x","article-title":"Ultraviolet A1 phototherapy for treatment of acrosclerosis in systemic sclerosis: Controlled study with half-side comparison analysis","volume":"23","author":"Durand","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0870","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0781.2004.00081.x","article-title":"Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. A clinico-pathologic study","volume":"20","author":"El-Mofty","year":"2004","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0875","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jaad.2005.11.1091","article-title":"A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis","volume":"54","author":"Knobler","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0880","first-page":"1586","article-title":"The efficacy of self-administered stretching for finger joint motion in Japanese patients with systemic sclerosis","volume":"33","author":"Mugii","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0885","first-page":"157","article-title":"Occupational therapy integrated with a self-administered stretching programme on systemic sclerosis patients with hand involvement","volume":"34","author":"Stefanantoni","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0890","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10067-009-1216-x","article-title":"Efficacy of connective tissue massage and Mc Mennell joint manipulation in the rehabilitative treatment of the hands in systemic sclerosis","volume":"28","author":"Maddali Bongi","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0895","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/09638280410001702405","article-title":"Evaluation of paraffin bath treatment in patients with systemic sclerosis","volume":"26","author":"Sandqvist","year":"2004","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0900","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jht.2008.06.009","article-title":"The effect of paraffin and exercise on hand function in persons with scleroderma: A series of single case studies","volume":"22","author":"Mancuso","year":"2009","journal-title":"J Hand Ther"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0905","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5014\/ajot.41.2.118","article-title":"Effects of splinting in the treatment of hand contractures in progressive systemic sclerosis","volume":"41","author":"Seeger","year":"1987","journal-title":"Am J Occup Ther"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0910","first-page":"162","article-title":"Systemic sclerosis: Rehabilitation as a tool to cope with disability","volume":"34","author":"Maddali-Bongi","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0915","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0030-4220(84)90309-8","article-title":"The nonsurgical treatment of microstomia in scleroderma: A pilot study","volume":"57","author":"Naylor","year":"1984","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0920","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00784-003-0216-5","article-title":"Effects of a nonsurgical exercise program on the decreased mouth opening in patients with systemic scleroderma","volume":"7","author":"Pizzo","year":"2003","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0925","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00296-010-1382-9","article-title":"The rehabilitation of facial involvement in systemic sclerosis: Efficacy of the combination of connective tissue massage, Kabat\u2019s technique and kinesitherapy: A randomized controlled trial","volume":"31","author":"Maddali-Bongi","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0930","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/09638288.2011.587589","article-title":"Effect of orofacial exercises on oral aperture in adults with systemic sclerosis","volume":"34","author":"Yuen","year":"2012","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0935","first-page":"1233","article-title":"The effects of warfarin on calcinosis in a patient with systemic sclerosis","volume":"20","author":"Yoshida","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0940","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/ard.2003.014431","article-title":"Low dose warfarin treatment for calcinosis in patients with systemic sclerosis","volume":"63","author":"Cukierman","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0945","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/art.1780330834","article-title":"The effect of diltiazem on calcinosis in a patient with the CREST syndrome","volume":"33","author":"Farah","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0950","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/rheumatology\/34.6.576","article-title":"Diltiazem induces remission of calcinosis in scleroderma","volume":"34","author":"Dolan","year":"1995","journal-title":"Rheumatology"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0955","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/ard.57.4.252","article-title":"Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression?","volume":"57","author":"Vayssairat","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0960","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archderm.1975.01630150077009","article-title":"Disodium etidronate therapy for dystrophic cutaneous calcification","volume":"111","author":"Rabens","year":"1975","journal-title":"Arch Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.clindermatol.2018.04.004_bb0965","first-page":"75","article-title":"Risedronate: a possible treatment for extraosseous calcification","volume":"15","author":"Fujii","year":"2005","journal-title":"Clin Calcium"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0970","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.62.3.267","article-title":"Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline","volume":"62","author":"Robertson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0975","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archderm.144.5.585","article-title":"Response of dystrophic calcification to intravenous immunoglobulin","volume":"144","author":"Schanz","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0980","first-page":"527","article-title":"Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis","volume":"5","author":"Fuchs","year":"1986","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0985","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.semarthrit.2011.11.007","article-title":"Treatment of systemic sclerosis-associated calcinosis: A case report of rituximab-induced regression of CREST-related calcinosis and review of the literature","volume":"41","author":"Daoussis","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0990","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10067-012-2124-z","article-title":"Rituximab-induced regression of CREST-related calcinosis","volume":"32","author":"De Paula","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb0995","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.semarthrit.2014.04.007","article-title":"Flare of calcinosis despite rituximab therapy","volume":"44","author":"Hurabielle","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1000","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/jcpt.12340","article-title":"Systemic sclerosis and calcinosis cutis: Response to rituximab","volume":"41","author":"Poormoghim","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2340\/00015555-2206","article-title":"Treatment of skin calcifications with intra-lesional injection of sodium thiosulphate: A case series","volume":"96","author":"Baumgartner-Nielsen","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1015","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/j.jaad.2013.03.022","article-title":"Intradermal sodium thiosulfate for exophytic calcinosis cutis of connective tissue disease","volume":"69","author":"Smith","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1020","first-page":"408","article-title":"Sodium thiosulfate for the treatment of calcinosis secondary to juvenile dermatomyositis","volume":"32","author":"Pagnini","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1025","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjd.14412","article-title":"Topical sodium metabisulfite for the treatment of calcinosis cutis: a promising new therapy","volume":"175","author":"del Barrio-D\u00edaz","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.semarthrit.2017.05.013","article-title":"Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases","volume":"47","author":"Goossens","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1035","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2017.0966","article-title":"Intralesional sodium thiosulfate treatment for calcinosis cutis in the setting of lupus panniculitis","volume":"153","author":"Gunasekera","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1040","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/j.jaad.2005.04.010","article-title":"Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy","volume":"53","author":"Sparsa","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jaad.2010.12.035","article-title":"Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy","volume":"66","author":"Sultan-Bichat","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1050","first-page":"177","article-title":"Safety and efficacy of extracorporeal shock wave therapy (ESWT) in calcinosis cutis associated with systemic sclerosis","volume":"34","author":"Blumhardt","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1055","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2133.1996.tb01166.x","article-title":"Digital calcification in systemic sclerosis: Effective treatment with good tissue preservation using the carbon dioxide laser","volume":"135","author":"Bottomley","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1060","first-page":"968","article-title":"Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser","volume":"29","author":"Chamberlain","year":"2003","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5090\/kjtcs.2015.48.2.151","article-title":"Surgical treatment of extensive tumoral calcinosis associated with systemic sclerosis","volume":"48","author":"Jung","year":"2015","journal-title":"Korean J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1070","first-page":"865","article-title":"A case of a generalized symptomatic calcinosis in systemic sclerosis","volume":"57","author":"Jecan","year":"2016","journal-title":"Romanian J Morphol Embryol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1075","first-page":"642","article-title":"Surgery of the hand in patients with systemic sclerosis: Outcomes and considerations","volume":"32","author":"Bogoch","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/archderm.145.2.212-b","article-title":"Surgical debridement of painful fingertip calcinosis cutis in CREST syndrome","volume":"145","author":"Saddic","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1085","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s00266-013-0224-z","article-title":"Surgical management of digital calcinosis in CREST syndrome","volume":"37","author":"Merlino","year":"2013","journal-title":"Aesthet Plast Surg"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00005792-198011000-00001","article-title":"Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon","volume":"59","author":"Rodnan","year":"1980","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1095","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00002281-199911000-00012","article-title":"Surgical management of the hand in scleroderma","volume":"11","author":"Melone","year":"1999","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0190-9622(96)90638-6","article-title":"The 585 nm flashlamp-pumped pulsed dye laser for the treatment of telangiectases in patients with scleroderma","volume":"35","author":"Ciatti","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1105","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2133.2012.11019.x","article-title":"Pilot study of intense pulsed light for the treatment of systemic sclerosis-related telangiectases","volume":"167","author":"Murray","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10103-013-1298-1","article-title":"Telangiectasis in CREST syndrome and systemic sclerosis: Correlation of clinical and pathological features with response to pulsed dye laser treatment","volume":"29","author":"Halachmi","year":"2014","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1115","first-page":"1422","article-title":"A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: A within-subject randomized trial","volume":"53","author":"Dinsdale","year":"2014","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1120","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1111\/ijd.13595","article-title":"Case series of pulsed dye laser treatment of telangiectasia in 23 patients with systemic sclerosis","volume":"56","author":"Burillo-Martinez","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1125","doi-asserted-by":"crossref","first-page":"804296","DOI":"10.1155\/2011\/804296","article-title":"Low-dose naltrexone for pruritus in systemic sclerosis","volume":"2011","author":"Frech","year":"2011","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1130","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.1780340315","article-title":"A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma","volume":"34","author":"Gruber","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1135","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1140","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-4632.2007.02887.x","article-title":"Evaluation of oral methotrexate in the treatment of systemic sclerosis","volume":"46","author":"Krishna Sumanth","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2018.04.004_bb1145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1684\/ejd.2015.2687","article-title":"Vitiligo-like depigmentation with perifollicular pigment retention in systemic sclerosis treated successfully with suplatast tosilate","volume":"26","author":"Fujimoto","year":"2016","journal-title":"Eur J Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X18300634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X18300634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T22:33:51Z","timestamp":1693607631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X18300634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":231,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0738081X18300634"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2018.04.004","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic sclerosis: Current concepts of skin and systemic manifestations","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2018.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}